Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody

PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. WO2019122882 patent describes a bispecific antibody with ant...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical patent analyst 2021-03, Vol.10 (2), p.67-72
Main Authors: Perez-Santos, Martin, Anaya-Ruiz, Maricruz, Sanchez-Esgua, Gabriela, Villafaña-Diaz, Luis, Barron-Villaverde, Diana
Format: Article
Language:English
Subjects:
antibody
bispecific
cancer
ICOS
immunotherapy
PD-L1
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. WO2019122882 patent describes a bispecific antibody with antitumor efficacy in CT26 model through of the depletion of T cells and improved ratio of CD8 T cells: T in tumor microenvironment. The anti-PDL-1/ICOS antibody is new; however, only preclinical assays are shown using colon carcinoma model. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this antibody surpasses the action of the combinatorial therapy in cancer.
ISSN:2046-8954
2046-8962
DOI:10.4155/ppa-2020-0035